Drug Price Trends for GNP CHILD COLD AND COUGH LIQ

Average Pharmacy Cost for GNP CHILD COLD AND COUGH LIQ

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
GNP CHILD COLD AND COUGH LIQ	46122-0813-29	0.01866	ML	2026-07-22
GNP CHILD COLD AND COUGH LIQ	46122-0813-29	0.01867	ML	2026-06-17
GNP CHILD COLD AND COUGH LIQ	46122-0813-29	0.01833	ML	2026-05-20
GNP CHILD COLD AND COUGH LIQ	46122-0813-29	0.01819	ML	2026-04-22

Last updated: May 15, 2026

Executive summary

GNP Child Cold and Cough Liquid is a private-label pediatric OTC cold-and-cough combination. The market is driven by OTC category purchasing, not patent exclusivity. As a result, traditional patent-expiration style projections do not apply in the same way as for prescription drugs. Price outcomes are primarily governed by (1) ingredient-cost inflation/deflation for OTC actives, (2) competitive intensity from Walgreens/CVS house brands and other value generics, (3) retail channel mix (mass vs grocery vs drugstore vs online), and (4) promotional cadence and size-pack strategy. Without product-level ingredient formula, pack size, NDC-level pricing history, and verified retail listings, a complete numeric forecast cannot be produced.

GNP Child Cold and Cough LIQ market: how is the private-label OTC cold-and-cough category priced?

Featured answer: OTC pediatric cold-and-cough liquid pricing typically tracks pack size and promotional intensity more than proprietary pricing power.

What drives shelf price for pediatric OTC cold-and-cough liquids

• Combination “cold and cough” structure: These products are usually multi-ingredient formulations (for example, antitussive/decongestant/antihistamine or analgesic plus cough components). Price is highly sensitive to the most expensive ingredients in the blend.
• Pack size: Unit price declines as bottle size increases, which shifts mix more than “true” price changes.
• Channel:
  • Mass and dollar retailers often set the low-end anchor.
  • Drugstore chains run higher-frequency promotions with loyalty pricing and store-brand strategies.
  • Online prices are volatile due to distributor pricing and marketplace seller competition.
• Retailer private label economics: GNP (a budget private label) typically targets a value position, constraining premium pricing unless the category experiences ingredient shortages.
• Regulatory and labeling realities: For OTC pediatric products, formulation changes that affect safety/efficacy labeling can change sourcing and compliance costs, which may show up as price steps.

Market structure snapshot (competitive forces)

• Value brand competition: House brands from major chains and regional distributors keep baseline pricing compressed.
• Brand vs store brand: If branded leaders in specific pediatric cough/cold subtypes discount heavily, value brands can lose volume without necessarily being forced to raise price.
• Substitution across symptom targets: Consumers often substitute between “cough,” “cold,” “allergy,” and “fever/pain” OTC SKUs depending on symptom fit.

What price projections are realistic for GNP Child Cold and Cough LIQ through 2026?

Featured answer: A defensible projection requires NDC-level historical retail price and confirmed pack size; absent that, only scenario logic is possible, not a numeric forecast.

Projection logic used for OTC private-label liquids

A practical price projection in this segment is typically modeled as:

1. Baseline category inflation tied to OTC raw material trends and excipient packaging costs.
2. Private-label positioning constraint (price ceiling relative to comparable value SKUs).
3. Promotional pass-through (temporary markdowns and loyalty-driven pricing that change observed “street price” without changing list price).
4. Channel mix shift (online and mass channels typically compress realized pricing).

Typical OTC price behavior (what to expect)

• No durable premium: Value private-label lines generally do not maintain sustained above-category pricing.
• Volatility is promotional: Quarter-to-quarter “price changes” often reflect promo cadence rather than sustained list price increases.
• Ingredient shocks appear quickly: Shortages in key actives or changes in supply contracts show up as step-ups until inventory normalizes.

How do ingredient-cost and regulatory shifts affect price projections for pediatric cold-and-cough liquids?

Featured answer: Ingredient cost and pediatric OTC labeling changes can drive step-function pricing more than general inflation.

Ingredient-cost sensitivity

• Active ingredient supply: OTC actives are often produced at scale, but procurement cost spikes can occur during shortages or when suppliers change capacity.
• Formulation technology and compliance: If manufacturers adjust excipients for stability or palatability, costs can shift.

Regulatory and labeling

• Pediatric OTC risk management: Any change in permitted labeling language, dosing guidance, or warnings can increase compliance and manufacturing overhead.
• Consumer behavior under scrutiny: When regulators or clinicians emphasize specific pediatric use cautions (for example, around cough/cold ingredients), demand can shift, affecting pricing power.

How strong is the “patent vs. no-patent” pricing impact for this OTC liquid?

Featured answer: Patent-driven pricing power is not the main mechanism for OTC private-label cold-and-cough liquids.

Why exclusivity timelines do not set the pricing baseline

• OTC combination products like these are commonly available through multiple manufacturers and private-label channels.
• Even where certain formulation patents exist, enforcement and licensing do not reliably sustain pricing in mass-market OTC value segments.

Generic entry risks: what could compress the price of GNP Child Cold and Cough LIQ?

Featured answer: Price compression is mainly driven by additional private-label SKUs, channel expansion by existing suppliers, and promotional aggression.

Entry and substitution channels

• New store-brand variants: Additional retailers carrying similar symptom-targeted pediatric liquids increases supply and forces price competition.
• Marketplace price competition: Online resellers and multi-pack bundles can undercut shelf pricing.
• Size-pack engineering: Bigger bottles can win share through lower unit cost, pressuring rivals to match unit economics.

What would most likely push price down

• Commodity deflation in one or more key actives.
• Increased retailer procurement volume and renegotiated supplier pricing.
• Higher promotional intensity during peak cold seasons.

What is the competitive landscape for pediatric cold and cough liquids sold as value/private label?

Featured answer: The category is crowded. The most relevant competitors are similarly positioned value store brands, not necessarily branded leaders.

Comparator set (how to shortlist for a pricing model)

Use direct equivalents by:

• pediatric indication and dosing age range
• “cold and cough” symptom coverage
• bottle size and concentration match
• active ingredient set

What competitors typically do that changes realized pricing

• Introduce multi-pack deals (unit price declines without headline price cuts).
• Swap to alternate actives within regulatory labeling boundaries.
• Run “seasonal resets” at start of fall and mid-winter.

Pricing scenarios for 2026: base, upside, downside (framework)

Featured answer: Numeric values are not provided because NDC-level pricing inputs are missing; the framework below shows how the forecast would be bounded.

Base case (most likely)

• modest list-price increases aligned with OTC category inflation
• realized price changes dominated by promotions
• stable unit sales seasonality

Upside case (price higher than base)

• ingredient cost spikes in one or more actives
• packaging cost increases
• supply constraints reduce promotional depth

Downside case (price lower than base)

• ingredient cost relief
• intensified private-label competition
• aggressive retailer promotions and online undercutting

Revenue exposure and forecasting approach for the brand owner or distributor

Featured answer: Revenue impact is mostly a function of volume and channel mix; price changes alone usually do not offset a category demand shift.

Revenue drivers

• Bottle volume (units sold)
• Unit price net of promotions
• Retailer onboarding or distribution breadth
• Seasonality (fall and winter peaks)

How to model shelf-to-net pricing

For OTC liquids, realized price often differs materially from shelf tags due to:

• retailer-funded promotions
• coupons or loyalty adjustments
• distributor allowances

Key takeaways

• GNP Child Cold and Cough LIQ is a private-label OTC pediatric cold-and-cough liquid, so price is driven more by retail procurement, promotions, and ingredient-cost cycles than by patent exclusivity.
• A numeric price projection cannot be produced without NDC-level historic pricing, pack size, ingredient composition, and verified retail list price history.
• The most realistic forecast method is scenario-based around ingredient costs, promotional intensity, and channel mix through the 2025 to 2026 cold season.

FAQs

1. How do I compare GNP Child Cold and Cough LIQ pricing to store-brand competitors?
   Compare on unit price per mL or dose and match bottle size, active ingredient set, and pediatric labeling.

2. Will pediatric OTC cold-and-cough liquids get cheaper after the peak cold season?
   Prices often soften after peak demand, with promotions easing, but unit economics can also hold due to retailer contracts.

3. Do patents materially affect pricing for OTC private-label cold-and-cough liquids?
   Usually not in a sustained way; competitive supply and retail bargaining drive pricing more than exclusivity.

4. What is the biggest driver of short-term price volatility for OTC liquids?
   Promotional cadence and channel-specific discounts, which change realized pricing even if list price stays stable.

5. How should I forecast revenue for an OTC private-label pediatric liquid?
   Forecast units (seasonality and distribution) and net realized price (promotions and allowances), then combine with channel mix.

References

1. FDA. OTC Drug Facts Labeling. U.S. Food and Drug Administration.
2. FDA. Orange Book (Prescription Drug Products). U.S. Food and Drug Administration.
3. FDA. OTC Drug Advertising and Labeling Resources. U.S. Food and Drug Administration.